Not currently recruiting at University of California Health

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

a study on Inflammatory Bowel Disease Ulcerative Colitis

Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at UCSD
Dates
study started
study ends around
Principal Investigator
by William Sandborn (ucsd)
Headshot of William Sandborn
William Sandborn

Description

Summary

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

Official Title

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

Keywords

Ulcerative Colitis, Inflammatory Bowel Disease, Inflammatory Bowel Diseases, mirikizumab

Eligibility

You can join if…

Open to people ages 18-80

  • Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.
  • Female participants must agree to contraception requirements.

You CAN'T join if...

  • Participants must not have developed a new condition, including cancer in the originator study.
  • Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
  • Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
  • Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.

Locations

  • University of California San Diego not yet accepting patients
    La Jolla 5363943 California 5332921 92037 United States
  • Clinical Applications Laboratories, Inc. completed
    San Diego 5391811 California 5332921 92103 United States
  • California Medical Research Associates completed
    Northridge 5377985 California 5332921 91324 United States
  • Care Access - Berkeley completed
    Berkeley 5327684 California 5332921 94705 United States
  • InSite Digestive Health Care completed
    Arcadia 5324477 California 5332921 91006 United States
  • Shengjing Hospital of China Medical University accepting new patients
    Shenyang 2034937 110004 China
  • The Second Afilliated Hospital of Hebei Medical University in progress, not accepting new patients
    Shijiazhuang 1795270 050000 China
  • Taian City Central Hospital in progress, not accepting new patients
    Taian 271000 China
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University in progress, not accepting new patients
    Wenzhou 1791388 315100 China
  • Wuhan Union Hospital in progress, not accepting new patients
    Wuhan 1791247 430022 China

Lead Scientist at University of California Health

  • William Sandborn (ucsd)
    Recall Faculty, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 940 research publications

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
ID
NCT03519945
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1063 study participants
Last Updated